Article
Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
The Journal of biological chemistry - 15 Dec 2017
Stepanova Victoria, Dergilev Konstantin V, Holman Kelci R, Parfyonova Yelena V, Tsokolaeva Zoya I, Teter Mimi, Atochina-Vasserman Elena N, Volgina Alla, Zaitsev Sergei V, Lewis Shane P, Zabozlaev Fedor G, Obraztsova Kseniya, Krymskaya Vera P, Cines Douglas B
Abstract excerpt
Lymphangioleiomyomatosis (LAM) is a fatal lung disease associated with germline or somatic inactivating mutations in tuberous sclerosis complex genes (TSC1 or TSC2). LAM is characterized by neoplastic growth of smooth muscle-α-actin-positive cells that destroy lung parenchyma and by the formation of benign renal neoplasms called angiolipomas. The mammalian target of rapamycin complex 1 (mTORC1) inhibitor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.